The Department of Health and Human Services is seeking to acquire the Agilent NovoCyte Advanteon Flow Cytometer, a benchtop system for high-parameter cellular analysis in research and clinical laboratories. This opportunity is open to all businesses, as there is no set-aside. The presolicitation notice indicates that interested vendors should monitor the opportunity closely for bidding details, as it may lead to a competitive procurement process. The equipment will enhance research capabilities related to gene expression regulation and its implications in various diseases.
Analysis by Mindy, grounded in the SAM.gov notice.
Description
The NovoCyte Advanteon Flow Cytometer is a benchtop system designed for high-parameter cellular analysis in research and clinical laboratory settings. It is an advanced platform for multicolor flow cytometry that combines flexible hardware configurations with automated data acquisition and analysis capabilities. The Section on Regulatory Ribonucleic Acids conducts research on the regulation of gene expression by ribonucleic acid binding proteins and micro ribonucleic acids. These studies are critical to understanding how gene regulation is disrupted in diseases such as cancer, hearing loss, and diabetes. Understanding these processes supports the development of new therapeutic approaches. Acquisition of the NovoCyte Advanteon Flow Cytometer will significantly increase experimental throughput and improve the efficiency of research workflows supporting these projects.
Source: SAM.gov, as posted. Verify the current solicitation before responding.
Pursue this opportunity with Mindy
See who holds it now, who else is bidding, and draft your response — grounded in real government data, not generic AI.